Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNT-55
- Development stage
- Preclinical
- Lead developer
- Radiomedix
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PNT-55 is an early-stage radiopharmaceutical candidate being developed by Radiomedix for the treatment of glioblastoma (GBM) and pancreatic islet adenocarcinomas. As a radiopharmaceutical, it is designed to deliver targeted radionuclide therapy directly to tumor cells. While the specific molecular target and the radionuclide (isotope) utilized in PNT-55 have not been publicly disclosed in detail, the agent is part of Radiomedix's pipeline of targeted therapies for high-unmet-need oncology indications. The drug is currently in the early development or preclinical phase and is intended for intravenous administration.
Beyond the preview
Go deeper on PNT-55.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNT-55.